Big Drug, Small Panel: US FDA Adcomm For Eisai/Biogen’s Leqembi Includes Only Six Voting Members

 
• By Sue Sutter
  
Half dozen eggs (2)
Leqembi's clinical benefit and safety will be evaluated by just a half dozen voting experts at a 9 June advisory committee meeting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers